Prescription Drugs, Drug Applications and FDA Regulatory Compliance
A practical guide for domestic and foreign pharmaceutical companies navigating Investigational New Drug applications, New Drug Applications, generic drug submissions, biologic licensing, active pharmaceutical ingredients, establishment registration, product listing, manufacturing compliance and entry into the United States market.
Prescription Drug Development Is a Lifecycle, Not a Single FDA Filing
The development and commercialization of a prescription drug in the United States is a multidisciplinary process involving scientific research, nonclinical testing, clinical investigation, chemistry and manufacturing controls, regulatory submissions, facility compliance, labeling, pharmacovigilance and postmarket oversight. A company cannot lawfully market a new prescription drug merely because the product has been manufactured according to a private formula, sold successfully in another country or supported by favorable laboratory results.
The company responsible for the product must determine the correct U.S. regulatory pathway and provide the U.S. Food and Drug Administration with the information required for that pathway. Depending on the nature of the product, the appropriate submission may include an Investigational New Drug application, a New Drug Application, an Abbreviated New Drug Application or a Biologics License Application. The product may also rely on information incorporated by reference through a Drug Master File or other authorized regulatory mechanism.
The FDA’s Center for Drug Evaluation and Research, commonly known as CDER, evaluates most human drugs. CDER’s scientific teams include physicians, pharmacists, chemists, microbiologists, pharmacologists, toxicologists, statisticians, clinical pharmacologists, manufacturing specialists and other professionals. Their review is intended to determine whether the evidence supports the proposed use, whether the benefits outweigh the known and potential risks, whether the proposed labeling communicates the necessary information and whether the product can be manufactured consistently.
For foreign companies, the U.S. regulatory process must also be integrated with establishment registration, drug listing, importer identification, U.S. Agent representation, customs documentation and FDA import review. A scientifically promising drug can still encounter delays, detention or refusal if the commercial supply chain is not properly registered, listed and documented.
Understanding Prescription Drugs and FDA Oversight
A prescription drug is generally a drug that cannot be used safely except under the supervision of a practitioner licensed by law to administer or prescribe it. The prescription status may reflect toxicity, potential harmful effects, method of use, collateral measures necessary for safe use or the need for professional diagnosis and monitoring.
Prescription products include conventional small-molecule drugs, certain therapeutic proteins, specialized injectables, oncology treatments, anti-infective drugs, cardiovascular medicines, neurological therapies and many other products. The applicable application route depends on whether the sponsor is developing a new molecular entity, a new formulation or indication, a generic version of an approved drug or a biological product.
FDA approval does not mean that a product is free from risk. Instead, approval generally reflects FDA’s determination that the product’s benefits outweigh its known and potential risks for the intended population and conditions of use described in the approved labeling. This assessment depends on the quality and completeness of the application.
FDA oversight continues after approval through adverse-event reporting, application supplements, establishment inspections, manufacturing surveillance, field alerts, recalls, labeling updates, risk-management activities and enforcement when legal requirements are not met.
The sponsor’s responsibility
The company seeking authorization remains responsible for developing the product, selecting qualified investigators and manufacturers, generating reliable evidence, maintaining accurate records, submitting required safety reports and demonstrating that the drug can be manufactured under appropriate controls.
How FDA Becomes Involved in the Development of a New Drug
FDA’s role generally begins when a sponsor that has screened a new molecule for pharmacological activity and toxicity wants to study its diagnostic or therapeutic potential in humans.
Before human exposure, a sponsor normally performs discovery research and nonclinical studies intended to characterize pharmacology, toxicology, dose relationships, absorption, distribution, metabolism and excretion. The extent of the nonclinical program depends on the product, route of administration, expected duration of treatment, population, proposed clinical study and known risks.
At this stage, early interaction with CDER can be extremely valuable. Through a pre-IND meeting or other formal communication, a sponsor may obtain FDA feedback concerning the adequacy of planned toxicology studies, the proposed clinical protocol, manufacturing information, starting dose, dose-escalation strategy and safety-monitoring measures. FDA’s comments do not transfer responsibility for the program to the agency, but they can identify deficiencies before the sponsor commits substantial resources.
Identify and characterize a promising molecule, compound or biological candidate.
Evaluate pharmacology, toxicology and other factors relevant to initial human use.
Submit the proposed clinical program and conduct authorized human studies.
Compile clinical, nonclinical, manufacturing and labeling information for review.
Maintain quality, safety reporting, registration, listing and approved conditions.
Investigational New Drug Application
An Investigational New Drug application, or IND, is the mechanism through which a sponsor requests authorization to administer an investigational drug or biologic to humans and to ship the investigational product across state lines for clinical investigation. An IND is not a marketing approval. It permits clinical investigation under the conditions described in the submission and applicable regulations.
An IND commonly contains three broad categories of information: nonclinical pharmacology and toxicology data, manufacturing information and clinical protocols with investigator information. FDA evaluates whether the proposed study would expose participants to unreasonable and significant risk and whether the submission contains sufficient information to support the planned investigation.
Nonclinical Evidence
Animal and laboratory information should support the proposed starting dose, administration route, treatment duration and safety-monitoring strategy.
Manufacturing Information
The sponsor describes the drug substance, drug product, composition, manufacturing process, specifications, analytical controls, stability and packaging.
Clinical Protocols
Protocols identify the study population, objectives, design, endpoints, dose, eligibility criteria, safety procedures and investigator responsibilities.
Unless FDA notifies the sponsor that the investigation may begin sooner, a sponsor generally waits 30 calendar days after FDA receives the IND before initiating the proposed clinical trial. FDA may impose a clinical hold if human subjects would be exposed to unreasonable risk, investigators are not qualified, the investigator brochure is misleading or incomplete, or the submission lacks information necessary to assess risk.
IND compliance continues throughout development. Sponsors may need to submit protocol amendments, information amendments, expedited safety reports and annual reports. Changes in manufacturing, formulation, clinical design or investigator participation should be evaluated to determine whether an additional submission is required before implementation.
New Drug Application
A New Drug Application, or NDA, is the formal request for FDA approval to market a new pharmaceutical product in the United States. Information generated during nonclinical studies and clinical trials under the IND becomes part of the NDA, together with comprehensive chemistry, manufacturing, controls, labeling and administrative information.
The NDA must permit FDA reviewers to determine whether the drug is safe and effective for its proposed use, whether the proposed labeling is appropriate and whether the manufacturing methods and controls can preserve the drug’s identity, strength, quality and purity. A successful clinical program alone is not sufficient when the application contains unresolved manufacturing, analytical, facility or data-integrity deficiencies.
Scientific and Clinical Content
- Nonclinical pharmacology and toxicology
- Clinical pharmacology and biopharmaceutics
- Human safety and effectiveness data
- Statistical analyses and study reports
- Integrated benefit-risk information
Product and Manufacturing Content
- Drug substance and drug product information
- Manufacturing processes and controls
- Analytical methods and acceptance criteria
- Stability data and proposed shelf life
- Container-closure and facility information
During review, FDA may issue information requests, discipline-review letters, inspection observations or a complete response letter identifying deficiencies that prevent approval. Sponsors should maintain coordinated control of responses because an answer provided by the clinical team may affect labeling, while a manufacturing change may affect stability, validation, comparability or facility readiness.
Following approval, certain changes may require a prior-approval supplement, a changes-being-effected supplement or documentation in an annual report. Promotional claims must remain consistent with the approved labeling and must not be false or misleading.
Abbreviated New Drug Application
An Abbreviated New Drug Application, or ANDA, is submitted for FDA review and potential approval of a generic drug product. It is called abbreviated because an applicant generally does not independently repeat the complete nonclinical and clinical investigations used to establish the safety and effectiveness of the reference listed drug.
Instead, the generic applicant must demonstrate, among other requirements, that its product has the same active ingredient, strength, dosage form, route of administration and conditions of use as the reference product, subject to legally permitted differences. The applicant must also demonstrate bioequivalence and satisfy requirements concerning quality, manufacturing, labeling and patent certifications.
Pharmaceutical Equivalence
The proposed generic must meet applicable sameness and compendial requirements.
Bioequivalence
Evidence must show that the generic performs comparably to the reference product according to the applicable scientific standard.
Manufacturing Quality
The API, finished dosage form and associated facilities must satisfy applicable quality and CGMP expectations.
Labeling and Patents
The submission must address labeling comparability, exclusivities and required patent certifications or statements.
Generic-drug applicants and facilities may be subject to user fees under the Generic Drug User Fee Amendments. Applicable fees can include ANDA, Drug Master File, API-facility, finished-dosage-form-facility, contract-manufacturing-organization and generic-drug applicant program fees. Rates and payment instructions are published for each fiscal year and should be verified directly with FDA before filing or payment.
Biologics License Application
A Biologics License Application, or BLA, requests permission to introduce or deliver a biological product into interstate commerce. Biological products may include vaccines, blood products, cellular therapies, gene therapies, recombinant proteins, monoclonal antibodies and other products derived through complex biological systems.
Biological products can be highly sensitive to changes in raw materials, cell banks, culture conditions, purification, formulation, filling, storage and shipping. Therefore, process characterization and manufacturing consistency are central elements of the licensing review. The application must support the safety, purity and potency of the product and provide sufficient information for FDA to assess the manufacturing establishment.
Depending on the product, a BLA may be reviewed by CDER or by FDA’s Center for Biologics Evaluation and Research. Sponsors should identify the appropriate reviewing center and office early because development expectations, meeting pathways and submission details can vary according to product type.
BLA and NDA are not interchangeable labels
The correct pathway depends on the legal and scientific classification of the product. A developer should not assume that every injectable, protein-based or biotechnology product automatically follows the same application route.
Active Pharmaceutical Ingredients and Drug Master Files
An Active Pharmaceutical Ingredient, or API, is a substance or mixture of substances intended to be used in manufacturing a drug product and that becomes an active ingredient in that product. The API is intended to furnish pharmacological activity or another direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or function of the body.
API compliance is critical because a finished drug manufacturer relies on the identity, purity, strength and consistency of the drug substance. Risks can arise from inadequate impurity controls, cross-contamination, solvent residues, elemental impurities, microbiological contamination, data-integrity failures, unqualified suppliers or unauthorized process changes.
Supplier Qualification
Manufacturers should evaluate the API producer, manufacturing site, quality system, audit history, specifications, test methods and change-notification practices.
Quality Agreements
Written responsibilities should address testing, batch disposition, deviations, investigations, complaints, recalls, changes and regulatory communications.
Traceability
Records should connect each API lot to its producer, manufacturing site, certificates of analysis, testing, transportation and finished-product batches.
A Drug Master File may be used to provide confidential detailed information concerning facilities, processes or materials used in manufacturing, processing and packaging a human drug. A DMF is not independently approved. FDA reviews relevant DMF information in connection with an application that has properly referenced the file through a letter of authorization.
Foreign establishments that manufacture, repack, relabel or salvage APIs imported or offered for import into the United States may be required to register with FDA. Foreign registration submissions must also identify required U.S. Agent and importer information.
How CDER Assists Drug Developers
CDER provides formal opportunities for sponsors and applicants to discuss development programs with FDA. These interactions can help clarify the study design elements, endpoints, patient populations, statistical approaches, manufacturing information and other data needed to support a full and comprehensive assessment.
Meetings may occur before an IND, at the end of Phase 1 or Phase 2, before submission of an NDA or BLA, during application review or in connection with a generic-drug development program. The value of a meeting depends substantially on the quality of the sponsor’s preparation.
Effective Meeting Preparation
- Define the specific regulatory and scientific questions.
- Provide concise background and supporting data.
- Explain the sponsor’s proposed position.
- Identify alternatives when the preferred plan is not acceptable.
- Coordinate clinical, statistical and CMC positions.
Common Development Issues
- Selection of endpoints and comparators
- Patient eligibility and trial duration
- Dose selection and exposure-response analysis
- Nonclinical study requirements
- Manufacturing comparability and stability
FDA feedback should be carefully documented and incorporated into the company’s regulatory strategy. When a sponsor later departs from an agreed approach, the rationale and supporting evidence should be evaluated and, where appropriate, discussed with FDA before implementation.
Drug Establishment Registration and Product Listing
Domestic and foreign establishments engaged in manufacturing, repacking, relabeling or salvaging drugs for commercial distribution in the United States are generally required to register with FDA unless an exemption applies. Drug manufacturers must also provide required drug-listing information for products in commercial distribution.
Registration and listing are separate legal obligations. Registering a building does not automatically list every product, and listing a product does not constitute FDA approval. Likewise, receipt of an FDA Establishment Identifier or National Drug Code does not mean that FDA has approved the company, facility or product.
FDA Establishment Registration
Identifies the location and regulated operations performed at the manufacturing, repacking, relabeling or other covered drug establishment.
FDA Establishment Identifier
FDA may use an FEI number to identify an establishment in agency systems. An FEI is not a certificate of approval or a substitute for current registration.
Drug Product Listing
Provides required product, labeling, marketing-category, manufacturing and related information through electronic Structured Product Labeling submissions.
U.S. Agent and Importers
A foreign drug establishment must identify a qualified U.S. Agent and provide other required information concerning importers and parties responsible for U.S. entry.
Establishments generally must register shortly after beginning covered operations and renew registration annually during the statutory renewal period. Product listings must also be kept accurate and updated when required. Companies should verify that names, addresses, FEI information, labeler codes, NDC data, marketing categories, establishment roles and product-label files are consistent across submissions.
Misbranding
Drug products manufactured, prepared, propagated, compounded or processed at an establishment that is not duly registered, or products that are not properly listed, may be deemed misbranded under section 502(o) of the FD&C Act.
Distribution of a misbranded drug in interstate commerce is prohibited. For imported products, apparent registration or listing violations may contribute to detention, refusal of admission, import alerts or requests for supporting records. Registration must therefore be treated as an active compliance obligation rather than a one-time administrative purchase.
Current Good Manufacturing Practice and Facility Readiness
FDA application approval and establishment registration do not replace Current Good Manufacturing Practice requirements. Drug products and APIs must be manufactured, processed, packed and held under controls appropriate to their legal category and stage of development.
A quality system should provide reliable control of personnel, facilities, equipment, components, containers, closures, production, laboratory operations, records, investigations, complaints, stability and distribution. Written procedures must reflect actual operations. Records should be complete, contemporaneous, attributable and protected against unauthorized alteration.
Quality Systems
The quality unit needs adequate authority to approve or reject materials, procedures, investigations, specifications and finished batches.
Data Integrity
Laboratory and production data must be accurate, complete, secure and available for review throughout the required retention period.
Inspection Readiness
Facilities should be able to retrieve records, explain systems, identify responsible personnel and respond promptly to FDA investigators.
FDA may inspect a manufacturing establishment before approving an application and may conduct surveillance or for-cause inspections after approval. Significant observations can delay approval, result in a warning letter, affect import status or lead to additional enforcement action.
International Manufacturers, Exporters and Importers
Companies located in Europe, Asia, Latin America and Africa may participate in the U.S. drug supply chain as application holders, API manufacturers, finished-dosage-form manufacturers, contract laboratories, packagers, labelers, exporters or intellectual property owners. Each role creates different compliance responsibilities.
Foreign approval does not automatically authorize U.S. marketing. A product approved by a European, Asian, Latin American or African regulatory authority must still satisfy the applicable U.S. requirements before commercial introduction. Differences may exist in formulation, indications, specifications, labeling, manufacturing sites, pharmacopoeial standards and postmarket obligations.
Before Exporting to the United States
- Confirm the product’s legal marketing pathway.
- Verify application approval or other lawful marketing status.
- Register every establishment required to register.
- Submit and maintain accurate drug listings.
- Confirm U.S. Agent and importer information.
- Review labels and electronic listing files.
Before the First Commercial Shipment
- Align invoice, entry and product identity information.
- Confirm manufacturer and application-holder relationships.
- Check NDC, labeler-code and listing status.
- Prepare approval and supply-chain documentation.
- Establish procedures for FDA holds and inquiries.
- Coordinate with the customs broker and importer.
The importer of record, customs broker, distributor, application holder, U.S. Agent and regulatory consultant may perform different functions. Companies should define these responsibilities through written agreements and avoid assuming that one commercial partner automatically fulfills every FDA and customs role.
Services Provided by U.S. FDA Consultants
FDA consultants can help companies identify regulatory obligations, organize submissions and prepare for interactions with the agency. Consultants do not approve products and cannot guarantee FDA acceptance, but qualified support can reduce preventable errors and improve coordination among scientific, manufacturing, commercial and legal teams.
Regulatory Pathway Assessment
Evaluate the product, intended use, active ingredients, reference products and available evidence to identify potential IND, NDA, ANDA, BLA or other requirements.
FDA Meeting Support
Assist with meeting requests, briefing packages, regulatory questions, presentation preparation, meeting participation and follow-up documentation.
Submission Coordination
Support application planning, document inventories, gap assessments, response management and coordination of clinical, nonclinical and CMC content.
Establishment Registration
Prepare and maintain registration submissions, U.S. Agent information, FEI-related records and annual renewal documentation.
Drug Listing and NDC Support
Assist with labeler codes, NDC configurations, Structured Product Labeling files, marketing-category review and product-listing updates.
Labeling Compliance
Review prescribing information, container labels, carton labeling, medication guides and other materials for consistency with applicable requirements.
API and Supplier Compliance
Evaluate API documentation, supplier qualification, quality agreements, DMF references, change controls and supply-chain traceability.
Inspection Readiness
Conduct document reviews, mock inspections, personnel preparation, observation assessments and corrective-action planning.
Import Compliance Support
Review establishment, listing, application and shipment information and assist with FDA detention, entry-document or compliance inquiries.
Integrate FDA Compliance Throughout the Drug Development Process
Successful access to the U.S. prescription-drug market requires more than a promising molecule or a manufacturing facility. A sponsor must select the correct application pathway, generate reliable scientific evidence, control the API and finished product, maintain compliant manufacturing systems and satisfy establishment registration and drug listing obligations.
The IND supports the transition from nonclinical development to human investigation. The NDA presents the evidence supporting approval of a new drug. The ANDA provides the pathway for a qualifying generic product. The BLA supports licensure of an applicable biological product. The API and its manufacturing controls remain central to the quality of every finished dosage form.
Engaging with CDER early on helps clarify the specific study designs and data needed for a thorough evaluation. However, the sponsor is ultimately accountable for ensuring the entire program is complete and reliable.
Careful early planning, rigorous record-keeping, and a unified regulatory approach are essential to avoid expensive oversights later in the development process.
Finally, both domestic and international companies must recognize that FDA approval, facility registration, product listing, U.S. Agent designation, and import paperwork are separate compliance steps. Falling short in even one of these areas can derail an otherwise solid drug product launch.
Prepare Your Drug Product for the U.S. Market
ITB HOLDINGS LLC provides U.S. FDA consulting support to domestic and foreign pharmaceutical companies, API manufacturers, finished-dosage-form manufacturers, exporters, importers and distributors.
Request assistance with drug establishment registration, annual renewal, U.S. Agent representation, labeler codes, National Drug Codes, drug product listings, labeling review, application planning, inspection readiness and import compliance.
